Seres Therapeutics Swings to $5.7M Net Income in FY2025, Eyes Q2 2026 SER-155 Data
MCRB sits 37% above its 52-week low of $6.53 on light trading volume (0.3× avg).
Summary
Seres Therapeutics reported a significant financial turnaround, achieving a net income from continuing operations of $5.7 million for the full year 2025, a substantial improvement from a $125.8 million net loss in 2024. This positive shift was primarily driven by lower operating expenses and a $75 million gain on sale from installment payments received from Nestle. The company also provided key business updates, including an expected Q2 2026 clinical data readout for the investigator-sponsored SER-155 study in immune checkpoint-related enterocolitis. Additionally, Seres is advancing its SER-603 program for inflammatory bowel disease and actively seeking partnerships and funding to support its pipeline, particularly for the Phase 2-ready SER-155 program for allo-HSCT. This financial improvement and clear pipeline catalysts are material for the small-cap biotech, though the leadership changes mentioned were previously disclosed in an 8-K on March 2nd.
At the time of this announcement, MCRB was trading at $8.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.8M. The 52-week trading range was $6.53 to $29.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.